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5-Selenophene-modified 5'-O-DMT-protected uridine 1b:
A mixture of 5'-O-DMTprotected 5-iodouridine 1a [S1] (1.0 g, 1.49 mmol, 1.0 equiv), 2-(tri-nbutylstannyl)selenophene [S2] (1.37 g, 3.27 mmol, 2.2 equiv) and bis(triphenylphosphine)-palladium(II) chloride (0.084 g, 0.12 mmol, 0.08 equiv) was dissolved in anhydrous dioxane (25 ml). The reaction mixture was heated at 90 C for 2 h and filtered through celite pad. The celite pad was washed with dichloromethane (2  20 ml), filtrate was evaporated and the resulting residue was purified by silica gel column chromatography to afford compound 1b as an off white foam (0.71 g, 71% yield). TLC (CH2Cl2:MeOH = 95:5 with few drops of Et3N); Rf = 0.36; 1 H NMR (400 MHz, CDCl3): δ (ppm) 8.02 (s, 1H), 7.85 (dd, J1 = 5.0 Hz, J2 = 1.4 Hz, 1H), 7. 2H), 4H), 3H), 2H), 4H), 5.99 (d, J = 4.8 Hz, 1H) 162.2, 158.7, 151.0, 144.4, 136.3, 135.6, 135.5, 132.0, 130.1, 130.1, 128.9, 128.2, 128.1, 127.2, 124.7, 113.4, 112.2, 90.7, 86.9, 84.8, 75.6, 71.2, 63.4, 55.3 ; HRMS: m/z Calcd. for C34H33N2O8Se M+H  = 677.1402, found = 677.1394.
5-Selenophene-modified 2'-O-TBDMS protected uridine 1c:
Compound 1b (0.95 g, 1.41 mmol, 1.0 equiv) and silver nitrate (0.62 g, 3.65 mmol, 2.6 equiv) were dissolved in anhydrous pyridine (4.8 ml). To the above solution was added anhydrous THF (14 ml). After stirring for 10 min tert-butyldimethylsilyl chloride (TBDMS-Cl, 0.55 g, 3.65 mmol, 2.6 equiv) was added. Reaction mixture was stirred for additional 0.5 h and filtered through celite pad. Celite pad was washed with ethyl acetate (2  15 ml) and the combined organic solution was then washed with 5 % sodium bicarbonate (20 ml) followed by brine solution (20 ml). The organic extract was dried over sodium sulphate and evaporated. The resulting crude residue was purified by silica gel column chromatography to afford the product 1c as a white solid (0.57 g, 52% yield 161.3, 158.8, 149.4, 144.4, 136.1, 135.4, 135.3, 132.6, 132.2, 130.2, 130.1, 128.9, 128.2, 128.1, 127.3, 124.9, 123.9, 113.4, 88.0, 87.0, 84.0, 75.8, 71.3, 63.4, 55.4, 25.8, 18 .1, -4.5, -4.9; HRMS: m/z Calcd. for C40H46N2O8SeSiNa M+Na  = 813.2086, found = 813.2123.
5-Selenophene-modified uridine phosphoramidite substrate 2:
To a solution of compound 1c (0.41 g, 0.52 mmol, 1.0 equiv) in anhydrous dichloromethane (4.1 ml) was added N,Ndiisopropylethylamine (0.226 mL, 1.30 mmol, 2.5 equiv) and stirred for 10 min. To this solution was slowly added 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (0.14 mL, 0.63 mmol, 1.2 equiv) and the reaction mixture was stirred for 12 h. The solvent was evaporated to dryness and the residue was redissolved in ethyl acetate (20 ml), which was washed with 5% sodium bicarbonate solution (15 ml) followed by brine solution (15 ml). The organic extract was dried over sodium sulphate, evaporated and the crude solid residue was purified by column chromatography to afford the product 2 as a white solid (0.33 g, 64%). TLC (petroleum ether:EtOAc = 60:40 with few drops of Et3N); Rf = 0.40; Analytical data was obtained using one of the diastereomers, which eluted first.
1 H NMR (400 MHz, CDCl3): δ (ppm) 8.03 (s, 1H), 7.86-7.84 (m, 1H), 7.44-7.42 (m, 2H), 7.32-7.28 (m, 5H), 7.25-7.20 (m, 2H), 6.78-6.70 (m, 6H) 161.3, 158.8, 149.4, 144.4, 135.4, 132.8, 132.0, 130.3, 130.3, 130.2, 128.9, 128.4, 128.2, 128.1, 127.3, 124.8, 113.4, 87.6, 87.0, 84.2, 75.8, 74.9, 63.4, 55.4, 43.6, 43.5, 29.8, 25.8, 24.8, 22.7, 20.3, 18.1, -4.4, -4.7; 31 P NMR (162 MHz, CDCl3): δ (ppm) 151.6; HRMS: m/z Calcd. for C49H63N4O9PSeSiNa M+Na  = 1013.3165, found = 1013.3191.
4. Solid-phase synthesis of selenophene-modified RNA ON 3: RNA ON 3 was synthesized on a 1 μmole scale using CPG solid support (1000 Å). Standard synthesis cycles employed for 2'-O-TBDMS-protected phosphoramidite substrates was used. While incorporation of native 2'-O-TBDMS-protected phosphoramidites was performed with a coupling time of 10 min (two times), incorporation of 5-selenophene-modified-2'-O-TBDMS-protected phosphoramidite substrate 2 was performed with a coupling time of 15 min (two times). The coupling efficiency for phosphoramidite substrate 2 based on trityl monitor-assay was found to be ~40%. After deprotection of trityl group on the synthesizer, the solid support was treated with a 1:1 solution of 10 M methylamine in ethanol and water (1.5 mL) for 12 h at RT. The mixture was centrifuged and the supernatant was evaporated to dryness on a Speed Vac. The residue was dissolved in DMSO (100 L) and was added TEA.3HF (150 L). The resulting solution was heated at 65 °C for 2.5 h and was brought to RT. The completely deprotected ON solution was lyophilized and was purified by PAGE (20% gel) under denaturing conditions. The band corresponding to the full-length product was identified by UV shadowing. The ON was extracted with ammonium acetate buffer (0.5 M, 3 ml) and desalted using a Sep-Pak classic C18 cartridge. A 1 mol scale synthesis gave ~100 nmol of the labeled RNA after PAGE purification. See Figure S2 for HPLC chromatogram and mass spectrum of purified ON 3. The selenophene-modified uridine was stable under solid-phase ON synthesis conditions. Standard deprotection and purification protocols (PAGA and HPCL) were used and the selenophene label was found to be stable and did not get oxidized. Under crystallization conditions also the modification was found to be stable (See section 9).
5. MALDI-TOF mass analysis of selenophene-modified RNA ON 3: 2 µL of the modified ON 3 (~200 µM) was combined with 1 µL of ammonium citrate buffer (100 mM, pH 9), 2 µL of a DNA internal standard (200 µM) and 4 µL of saturated 3-hydroxypicolinic acid solution. The sample was desalted using an ion-exchange resin (Dowex 50W-X8, 100-200 mesh, ammonium form), spotted on the MALDI plate and air dried. Figure S1 . Design of "two-in-one" ribonucleoside probe for RNA analysis in solution and solid-state. In this design, the fluorophore core and anomalous X-ray scattering Se atom are placed in the same scaffold so that they sense the same environment when incorporated into RNA ONs. 
Reconstitution of bacterial A-site RNA models:
A-site containing selenophene-modified uridine at position 1406 (3•4) and control native (5•4) A-site models were assembled by heating 1:1 mixture of respective ONs (40 µM) in buffer (30 mM sodium cacodylate, 100 mM NaCl, pH 6.8) at 70 °C for 3 min. Samples were slowly cooled to RT and placed on ice for 30 min before fluorescence, CD and thermal melting analysis were performed. For fluorescence and thermal melting analysis, samples of A-site constructs were diluted with cacodylate buffer to a final RNA concentration of 2 µM. For CD analysis, 5 µM concentration of A-site constructs was used.
7. CD analysis: 5 µM of the control unmodified and selenophene modified A-site constructs was used in the CD experiments. CD spectra were collected from 350 to 220 nm using a quartz cuvette (Sterna Scientific, path length 2 mm) on a Jasco J-815 CD spectrometer using 1 nm bandwidth at 20 °C. Experiments were performed in duplicate wherein each spectrum was an average of three scans. The spectrum of buffer was subtracted from all sample spectra. Figure S3 . (A) CD spectra (5 M) of control unmodified A-site RNA 5•4 (blue) and Se U-modified Asite RNA 3•4 (red). Both unmodified and modified ONs showed similar CD profiles, which were in consensus with the literature report. [S3] (B) UV-thermal melting profile of control A-site RNA 5•4 (blue) and Se U-modified A-site RNA 3•4 (red) at 260 nm. Tm values for 5•4 and 3•4 were found to be 59.0 ± 0.7 °C and 58.8 ± 0.3 °C, respectively. For experimental details see section 6 and 7.
Fluorescence monitoring of aminoglycosides binding to selenophene modified A-site construct 3•4:
400 μL of A-site construct 3•4 (2 μM) was taken in a micro fluorescence cuvette (Hellma, path length 1.0 cm) and titrated by adding 1 μL of stock solutions of increasing concentration of aminoglycosides. After each addition of aminoglycoside the sample was excited at 330 nm with excitation and emission slit widths of 4 and 6 nm, respectively, and changes in fluorescence intensity at emission maximum (450 nm) were measured. The aminoglycoside was added till the fluorescence saturation point. The total volume change upon addition of aminoglycosides throughout the titration was ≤ 4%. A spectral blank of cacodylate buffer in the absence of RNA and aminoglycoside was subtracted from all titrations. A control titration experiment performed as above by adding buffer (instead of aminoglycosides) to A-site 3•4 did not result in detectable changes in fluorescence indicating that repeated excitation of the sample did not cause photodegradation or photobleaching of the labeled A-site. Therefore, the increase in fluorescence intensity observed upon addition of aminoglycoside antibiotics to A-site reflects the ability of selenophene-modified uridine to report RNA-ligand binding. All fluorescence experiments were performed in triplicate at 20 °C. Normalized fluorescence intensity (FN) versus log of aminoglycoside (AG) concentration plots were fitted using Hill equation (OriginPro 8.5.1) to determine the apparent dissociation constant (KD) values for the binding of aminoglycosides to A-site construct. [S4,S5] One-site binding model was used.  2 values for the curve fits were found to be very close to unity. Hill coefficient (n) was in the range of 1.2-1.5. 
Crystallization and Data Collection:
The Se U-modified A-site model RNA 3•4 was assembled by annealing stoichiometric amounts of the ON 3 and 4 in 10 mM sodium cacodylate, pH 6.5 by heating to 65 °C for 4 min followed by snap cooling on ice for 10 min followed by slow warming to room temperature. After annealing, the RNA was crystallized at 22 °C by hanging drop vapor diffusion. For crystallization, 1 μL of 0.2 mM RNA was mixed with an equal volume of crystallizing solution containing 2.40-2.55 M ammonium sulfate, 10 mM magnesium acetate, and 40 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH 5.6). Crystals grew over the course of four to seven months after equilibration against 700 μL of well solution containing crystallizing solution. Crystals were flash-cooled in liquid nitrogen. Crystal screening and X-ray diffraction data were collected at 110 K on a Rigaku rotating anode X-ray generator (λ = 1.54 Å) equipped with a MAR345 imaging plate detector system. Datasets were processed, integrated, and scaled with the HKL2000 package. [S6] Structure solution and refinement: The three-dimensional structures of the Se U-modified Asite RNA construct was solved by molecular replacement with the program Phaser [S7] using a previously determined structure, [S5] as the search model and refined by the program Refmac [S8] both within the CCP4 package. [S9] Subsequent iterative rounds of manual building and refinement, alternating between Refmac and manual rebuilding in Coot, [S10] were based on the obtained 2Fo-Fc and Fo-Fc density maps. Final refinement was carried out in PHENIX [S11] with individual isotropic atomic displacement parameters and water picking. Crystallographic data collection and refinement statistics are provided in Table S1 . Atomic coordinates and structure factors of the [a] Centroid to centroid distance has been reported. Py = pyrimidine ring; Im = imidazole ring of guanine; Se = selenophene ring of Se U ribonucleoside. Figure S10 . Superimposition of the Se U-modified A-site RNA and native A-site RNA bound to neomycin B (yellow; PDB: 2A04).
[S25] Superimposed SeU nucleoside (cyan) is only shown. 
